Targeting cytochrome P450 enzymes: A new approach in anti-cancer drug development
- 24 May 2007
- journal article
- review article
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 15 (15) , 5047-5060
- https://doi.org/10.1016/j.bmc.2007.05.046
Abstract
No abstract availableKeywords
This publication has 150 references indexed in Scilit:
- Enzymatic properties of human CYP2W1 expressed in Escherichia coliBiochemical and Biophysical Research Communications, 2006
- Effects of the potential chemopreventive agent DMU-135 on adenoma development in the ApcMin+ mouseInvestigational New Drugs, 2006
- Tumor-specific expression of the novel cytochrome P450 enzyme, CYP2W1Biochemical and Biophysical Research Communications, 2006
- Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens: Synthesis, in Vitro Biological Activity, Pharmacokinetics, and Antitumor Activity in the LAPC4 Human Prostate Cancer Xenograft ModelJournal of Medicinal Chemistry, 2005
- Molecular determinants of resistance to antiandrogen therapyNature Medicine, 2003
- The cancer preventative agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enzyme CYP1B1British Journal of Cancer, 2002
- 25-Hydroxy-Vitamin D Metabolism in Human Colon Cancer Cells during Tumor ProgressionBiochemical and Biophysical Research Communications, 2001
- Cytochrome P-450 C21scc: One enzyme with two actions: Hydroxylase and lyaseThe Journal of Steroid Biochemistry and Molecular Biology, 1991
- Cloning and expression of cDNA encoding 25‐hydroxyvitamin D3 24‐hydroxylaseFEBS Letters, 1991
- Binding of 2-hydroxyestradiol and 4-hydroxyestradiol to estrogen receptors from human breast cancersJournal of Steroid Biochemistry, 1989